Cargando…

Mitomycin and 5‐fluorouracil for second‐line treatment of metastatic squamous cell carcinomas of the anal canal

BACKGROUND: Metastatic squamous cell carcinomas (SCC) of the anal canal are rare and there is no international consensus on their second‐line management. 5‐Fluorouracil (5‐FU) and mitomycin in combination with radiotherapy is the standard for locally advanced forms but its efficacy in metastatic sta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saint, Angélique, Evesque, Ludovic, Falk, Alexander T., Cavaglione, Gérard, Montagne, Lucile, Benezery, Karen, Francois, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853831/ https://www.ncbi.nlm.nih.gov/pubmed/31524335 http://dx.doi.org/10.1002/cam4.2558

Ejemplares similares

Efficacy and tolerance of high-dose-rate brachytherapy boost after external radiotherapy in the treatment of squamous cell carcinoma of the anal canal
por: Bertin, Emilien, et al.
Publicado: (2018)

VITAL phase 2 study: Upfront 5‐fluorouracil, mitomycin‐C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09‐02)
por: Feliu, Jaime, et al.
Publicado: (2019)

Clinical response assessment after contact X-Ray brachytherapy and chemoradiotherapy for organ preservation in rectal cancer T2-T3 M0: The time/dose factor influence
por: Benezery, Karen, et al.
Publicado: (2020)

A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10–2 trial)
por: Murofushi, Keiko Nemoto, et al.
Publicado: (2022)

Interstitial high-dose rate brachytherapy as boost for anal canal cancer
por: Falk, Alexander Tuan, et al.
Publicado: (2014)

Capecitabine/Mitomycin versus 5-Fluorouracil/Mitomycin in Combination with Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy for Anal Cancer
por: Mineur, Laurent, et al.
Publicado: (2023)

Concurrent Chemoradiation With 5-Fluorouracil and Mitomycin in Squamous Cell Carcinoma of the Rectum
por: Sethi, Ashish K
Publicado: (2021)

Nonplatinum‐based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population‐based Danish anal cancer group study
por: Truelsen, Christina Glismand, et al.
Publicado: (2021)

Replacing 5-fluorouracil by capecitabine in localised squamous cell carcinoma of the anal canal: systematic review and meta-analysis
por: Souza, Karla T, et al.
Publicado: (2016)

Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Alliot, C
Publicado: (2006)

Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma
por: Thind, Govin, et al.
Publicado: (2014)

Reply: Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2006)

Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma
por: Werner, Dominique, et al.
Publicado: (2013)

Limited Value of Staging Squamous Cell Carcinoma of the Anal Margin and Canal Using the Sentinel Lymph Node Procedure: A Prospective Study with Long-Term Follow-Up
por: de Jong, Johannes S., et al.
Publicado: (2010)

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma
por: Kim, Stefano, et al.
Publicado: (2022)

Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2005)

The impact of anaemia on treatment outcome in patients with squamous cell carcinoma of anal canal and anal margin
por: Oblak, Irena, et al.
Publicado: (2016)

Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma
por: Zampino, Maria G, et al.
Publicado: (2011)

Construction and validation of a prognostic nomogram for anal squamous cell carcinoma
por: Yang, Ningning, et al.
Publicado: (2021)

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer
por: Chibaudel, Benoist, et al.
Publicado: (2016)

Melanoma of the anal canal
por: Parra, Rogerio Serafim, et al.
Publicado: (2010)

Narrow-band imaging for diagnosis of squamous cell carcinoma in the anal canal
por: Takeuchi, Yoji, et al.
Publicado: (2017)

Salvage Abdominoperineal Resection for Squamous Cell Anal Cancer: A 30-Year Single-Institution Experience
por: Hagemans, J. A. W., et al.
Publicado: (2018)

The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal
por: Eng, Cathy, et al.
Publicado: (2014)

Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.
por: Topham, C., et al.
Publicado: (1991)

Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients
por: Golan, Talia, et al.
Publicado: (2015)

Beware of anal fissures: pemphigus vulgaris of the anal canal
por: Karatzi, Chara, et al.
Publicado: (2019)

Intraoperative Mitomycin C Bladder Instillation During Radical Nephroureterectomy Is Feasible and Safe
por: Nadler, Naomi, et al.
Publicado: (2021)

Chemoradiotherapy in squamous cell carcinoma of the anal canal: a single institution experience
por: Kim, Kyung Hwan, et al.
Publicado: (2013)

Early Squamous Cell Carcinoma of the Anal Canal Resected by Endoscopic Submucosal Dissection
por: Tamaru, Yuzuru, et al.
Publicado: (2015)

Endoscopic submucosal dissection to treat squamous cell carcinoma in situ of the anal canal
por: Lajin, Michael, et al.
Publicado: (2022)

Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma
por: Azzi, Georges, et al.
Publicado: (2022)

Social determinants of stage IV anal cancer and the impact of pelvic radiotherapy in the metastatic setting
por: Repka, Michael C., et al.
Publicado: (2017)

Topical Mitomycin-C versus Subconjunctival 5-Fluorouracil for Management of Bleb Failure
por: Pakravan, Mohammad, et al.
Publicado: (2011)

A Comparative Study of Mitomycin C and 5-Fluorouracil Trabeculectomy in West Africa
por: Anand, Nitin, et al.
Publicado: (2012)

Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab
por: Matsunaga, Mototsugu, et al.
Publicado: (2016)

Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution
por: Holliday, Emma B, et al.
Publicado: (2022)

Malignancies diagnosed before and after anal squamous cell carcinomas: A SEER registry analysis
por: Jani, Krupa S., et al.
Publicado: (2021)

Feasibility of definitive chemoradiation therapy with nedaplatin and 5-fluorouracil in elderly patients with esophageal squamous cell carcinoma: A retrospective study
por: Watanabe, Akinori, et al.
Publicado: (2018)

Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5‐fluorouracil and leucovorin combination as first‐ or second‐line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial
por: Innominato, Pasquale F., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6rk1bm72o7al6qccku9e7hrpuo